Drug Database
BU

bupropion (Forfivo / Forfivo XL / INT0004/2006)

✓ Approved

Cary Pharmaceuticals Inc. · SLC6A2 · 小分子

什么是 bupropion?

bupropion 是一种小分子,由Cary Pharmaceuticals Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Forfivo, Forfivo XL, INT0004/2006
公司Cary Pharmaceuticals Inc.
药物类别小分子
分子靶点SLC6A2, SLC6A3
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

bupropion 作用于 2 个分子靶点:

SLC6A2solute carrier family 6 member 2 (NAT1, NET)
SLC6A3solute carrier family 6 member 3 (PKDYS, DAT1)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

bupropion 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Psychiatric disordersBipolar I disorderPhase I
Psychiatric disordersMajor depressionPhase I

相关研究文献

PubMedFrontiers in pharmacology2026-11-17

Comparative efficacy and safety of nonhormonal prescription drugs for vasomotor symptoms in women with breast cancer: a systematic review and network meta-analysis.

Liao Yin-Sheng YS, Deng Yu-Ping YP, Song Jian-Li JL, Yu Xuan X et al.

Vasomotor symptoms (VMS) are common during and after breast cancer treatment, particularly among women receiving endocrine therapy. We compared the efficacy, acceptability, and safety of nonhormonal prescription pharmacological interventions for VMS in women with breast cancer or breast cancer survivors. We searched major databases and trial registries through July 2026 for randomized controlled trials comparing nonhormonal prescription drugs versus placebo or another eligible nonhormonal prescription drug in adult women with breast cancer-related VMS. The primary outcome was continuous VMS efficacy. Secondary outcomes included responder outcomes, all-cause discontinuation, discontinuation due to adverse events, any adverse events, and serious adverse events. We performed frequentist random-effects network meta-analysis, with Bayesian network meta-analysis as sensitivity analysis. Risk of bias was assessed using RoB 2, and certainty of evidence using a GRADE/NMA-GRADE approach. Eighteen publications, corresponding to 19 study/substudy records and 2,224 randomized or allocated participants, were included. Five interventions were significantly more effective than placebo: escitalopram (SMD -1.08, 95% CI -1.80 to -0.37), desvenlafaxine 50 mg (SMD -0.87, 95% CI -1.60 to -0.15), desvenlafaxine 100 mg (SMD -0.80, 95% CI -1.44 to -0.15), elinzanetant (SMD -0.51, 95% CI -0.95 to -0.07), and venlafaxine 75 mg (SMD -0.42, 95% CI -0.76 to -0.07). Heterogeneity was moderate (I2 = 44.9%), with no significant global or local inconsistency. Frequentist P-scores ranked the five significant drugs top, confirmed by Bayesian sensitivity. Elinzanetant had high-certainty evidence, whereas venlafaxine 75 mg and gabapentin 900 mg had moderate-certainty evidence. Escitalopram and desvenlafaxine had large effects, but the supporting evidence was sparse. Discontinuation outcomes showed no statistically significant differences versus placebo, but sparse safety networks precluded a reliable comparative safety hierarchy; these null findings should not be interpreted as evidence of equivalent tolerability. Nonhormonal prescription drugs are not interchangeable for breast cancer-related VMS. Elinzanetant provides the strongest high-certainty evidence among newer targeted options, and venlafaxine 75 mg is the best-supported conventional option. Escitalopram and desvenlafaxine remain promising but require further trials. Gabapentin 900 mg may be considered in selected patients, whereas sertraline, bupropion, gabapentin 300 mg, and clonidine are lower-priority options. https://www.crd.york.ac.uk/PROSPERO/view/CRD420261460108, identifier CRD420261460108.

PMID 43041301
阅读全文 →
PubMedInternational journal of molecular sciences2026-11-14

Dextromethorphan-Bupropion-Esketamine Triadic Pharmacology: Molecular Targets, Enzymatic Interactions, and Risk-Benefit Assessment of a Three-Agent Combination for Treatment-Resistant Depression.

Fagiolini Andrea A, Cuomo Alessandro A, Corrivetti Giulio G, Pinzi Mario M et al.

Dextromethorphan is extensively O-demethylated by cytochrome P450 2D6 (CYP2D6) to dextrorphan, and the two molecules do not share a target profile. Dextrorphan is the more potent N-methyl-D-aspartate (NMDA) channel blocker; the parent compound is the more potent serotonin transporter inhibitor; their sigma-1 affinities are comparable, so differences in sigma-1 engagement depend on exposure rather than intrinsic affinity. CYP2D6 activity therefore does not scale exposure to a fixed pharmacology; it determines which pharmacology is expressed. This review develops that principle and extends it to a three-agent system. From published unbound concentrations and functional potencies, we calculate a model-derived fractional-target-engagement index. Under the base-case inputs, CYP2D6 inhibition raises the serotonergic index approximately fourfold while reducing the NMDA channel index; deterministic sensitivity analysis shows that the direction is robust to one-at-a-time 0.5-fold to 2-fold perturbations but not to all joint extreme assumptions. Quinidine and bupropion are analyzed as mechanistically distinct proofs of concept, and quinidine-derived exposure estimates are not treated as quantitative surrogates for the dextromethorphan-bupropion steady state. The framework is then applied to the untested question of whether a boosted dextromethorphan combination and esketamine are redundant or complementary. The agents share an NMDA channel mechanism, while CYP2B6 pathway overlap remains a hypothesis-generating observation rather than evidence of clinically relevant competition. No controlled data on the three-agent combination exist, and no therapeutic recommendation is made.

PMID 43028281
阅读全文 →
PubMedThe American journal of psychiatry2026-11-13

Concerns About the Evidence Supporting Dextromethorphan-Bupropion in Depression.

Kennedy Kevin P KP

PMID 43021459
阅读全文 →
PubMedThe American journal of psychiatry2026-11-13

Concerns About the Evidence Supporting Dextromethorphan-Bupropion in Depression: Response to Kennedy.

Tabuteau Herriot H

PMID 43021457
阅读全文 →
PubMedFrontiers in psychiatry2026-11-12

Managing coexisting depression and substance use disorder: insights from clinical experience.

Schifano Fabrizio F, Martinotti Giovanni G, Wojnar Marcin M, Homem de Melo Inês I et al.

Comorbid major depressive disorder (MDD) and substance use disorder (SUD) occur frequently and are challenging to manage. The negative impact of these co-occurring conditions on patient quality of life, functional ability, and mortality necessitates timely diagnosis and a multifaceted treatment approach. However, there are few evidence-based clinical guidelines for these co-occurring conditions, further adding to the complexity of treatment. Here, we provide our perspective on the management of MDD in the context of SUD using clinical evidence and our experience. Due to the chronic, relapsing nature of these disorders, long-term follow-up is required to continually assess treatment efficacy and make adjustments where needed. Antidepressants frequently used for MDD, such as selective serotonin reuptake inhibitors (SSRIs), may show variable effectiveness in patients with comorbid SUD, and antidepressant selection should be individualized according to the patient profile, disease characteristics, and type of substance being misused. Treatment options with different pharmacodynamic profiles include agomelatine, bupropion, and vortioxetine. Serotonin antagonist and reuptake inhibitors (SARIs), such as trazodone, may offer advantages in select patients, given their safety profile and potential to address depressive features commonly seen with SUD. Importantly, collaboration between a range of healthcare professionals to provide psychoeducation and pharmacological management, alongside social support that includes family, friends, and/or caregivers is needed for treatment success. Further studies specifically assessing treatments for comorbid MDD and SUD are required. In addition, training is needed to increase medical expertise and lessen stigma, which can contribute to sub-standard care.

PMID 43017509
阅读全文 →
PubMedNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026-11-11

Antidepressants in postural orthostatic tachycardia syndrome (POTS): A scoping review.

Blitshteyn Svetlana S, Reiersen Angela M AM, Weinstock Leonard B LB, Speed Traci J TJ et al.

Postural orthostatic tachycardia syndrome (POTS) is one of the most common autonomic disorders with increasing prevalence and incidence after COVID-19 pandemic. Despite standard treatment of POTS consisting of nonpharmacologic and pharmacologic therapies that decrease heart rate and increase blood pressure and plasma volume, antidepressant medications are widely utilized in patients with POTS. We conducted a scoping review of literature to examine the published studies on the use of antidepressants and their efficacy in patients with POTS. We found only 2 studies, one retrospective chart review involving bupropion and second study of a randomized placebo-controlled crossover trial of a single dose of sertraline 50 mg. Both studies showed no benefits of these medications on orthostatic vital signs or orthostatic symptoms. A third study involving retrospective chart review did not examine medication efficacy, but found that nearly half of 120 patients with POTS were taking some type of antidepressant or antianxiety medication while only 15.7% were taking cardiovascular medications for treatment of POTS. Based on very limited available data, we conclude that antidepressants show no efficacy for treatment of POTS despite being widely utilized. Education of healthcare professionals regarding proper diagnosis and appropriate treatment of POTS is essential to instituting the right treatment and avoiding inappropriate use of antidepressants in this patient population.

PMID 43013113
阅读全文 →

注册免费账户还可查看另外 5634 篇文献

免费注册查看全部文献 →

了解更多bupropion